Kanabinoidy w leczeniu stwardnienia rozsianego Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2014
Słowa kluczowe:
kanabinoidy, stwardnienie rozsiane
##plugins.themes.bootstrap3.article.main##
Abstrakt
Spastyczność jest jednym z głównych objawów stwardnienia rozsianego wpływających na jakość życia chorych. Obecnie stosowane leczenie objawowe spastyczności nie jest w pełni satysfakcjonujące ani dla pacjentów, ani dla lekarzy. Kanabinoidy są nową opcją w terapii objawowej stwardnienia rozsianego. Zostały one zarejestrowane do leczenia objawowego spastyczności i bólu neuropatycznego w stwardnieniu rozsianym. Możliwość zastosowania kanabinoidów jako leków zmieniających naturalny przebieg choroby wymaga dalszych badań.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Flachenecker P., Henze T., Zettl U.K.: Spasticity in patients with multiple sclerosis – clinical characteristics, treatment and quality of life. Acta Neurol. Scand. 2014; 129(3): 154-62.
2. Rizzo M.A., Hadjimichael O.C., Preingerova J. et al.: Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 2004; 10(5): 589-595.
3. Grotenhermen F., Müller-Vahl K.: The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl. Int. 2012; 109(29-30): 495-501.
4. Leussink V.I., Husseini L., Warnke C. et al.: Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Ther. Adv. Neurol. Disord. 2012; 5(5): 255-66.
5. Fankhauser M.: Cannabis in der westlichen Medizin Cannabis und Cannabinoide. W: Pharmakologie, Toxikologie und therapeutisches Potential. Grotenhermen F. (red.). Wyd. 2. Hans Huber, Göttingen, 2004: 57-71.
6. Consroe P., Musty R., Rein J. et al.: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 1997; 38(1): 44-8.
7. Clark A.J., Ware M.A., Yazer E. et al.: Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004; 62(11): 2098-100.
8. Zajicek J., Fox P., Sanders H. et al.; UK MS Research Group: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517-26.
9. Zajicek J.P., Sanders H.P., Wright D.E. et al.: Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J. Neurol. Neurosurg. Psychiatry 2005; 76(12): 1664-9.
10. Wade D.T., Makela P., Robson P. et al.: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 2004; 10(4): 434-41.
11. Collin C., Davies P., Mutiboko I.K. et al., Sativex Spasticity in MS Study Group: Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 2007; 14(3): 290-6.
12. Novotna A., Mares J., Ratcliffe S. et al., Sativex Spasticity Study Group: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 2011; 18(9): 1122-31.
13. Freidel et al.: Treatment of specific symptoms session. Fri. 4, Oct. 15:30–17:30. P1111. ECTRIMS 2013.
14. Wright et al.: Late Breaking News session. Fri. 4, Oct. 15:30–17:30. P1206. ECTRIMS 2013.
15. Eltayb et al.: Long-term treatment monitoring session. Fri. 4, Oct. 15:30–17:30. P1041. ECTRIMS 2013.
16. García-Merino A.: Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev. Neurother. 2013; 13(3 Suppl 1): 9-13.
17. Hilliard A., Stott C., Wright S. et al.: Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis. ISRN Neurol. 2012; 2012: 802649.
18. Arroyo R., Massana M., Vila C.: Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int. J. Neurosci. 2013; 123(12): 850-8.
19. Rizzo M.A., Hadjimichael O.C., Preingerova J. et al.: Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 2004; 10(5): 589-595.
20. Montalban X., Wright S.: Trial period for new symptomatic treatments: lessons learnt from a Sativex in MS spasticity clinical trial. Mult. Scler. 2009; 15: S272.
21. Svendsen K.B., Jensen T.S., Bach F.W.: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460): 253.
22. Rog D.J., Nurmikko T.J., Friede T.: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812-9.
23. Langford R.M., Mares J., Novotna A. et al.: A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J. Neurol. 2013; 260(4): 984-97.
24. Kavia R.B., De Ridder D., Constantinescu C.S. et al.: Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler. 2010; 16(11): 1349-59.
25. Zajicek J.P., Apostu V.I.: Role of cannabinoids in multiple sclerosis. CNS Drugs 2011; 25(3): 187-201.
26. Corey-Bloom J., Wolfson T., Gamst A. et al.: Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 2012; 184(10): 1143-50.
27. Aldington S., Harwood M., Cox B. et al.: Respiratory Disease Research Group. Cannabis use and risk of lung cancer: a case-control study. Eur. Respir. J. 2008; 31(2): 280-6.
28. de Lago E., Moreno-Martet M., Cabranes A. et al.: Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 2012; 62(7): 2299-308.
29. Hasseldam H., Johansen F.F.: Cannabinoid treatment renders neurons less vulnerable than oligodendrocytes in Experimental Autoimmune Encephalomyelitis. Int. J. Neurosci. 2011; 121(9): 510-20.
30. Kozela E., Lev N., Kaushansky N. et al.: Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosislike disease in C57BL/6 mice. Br. J. Pharmacol. 2011; 163(7): 1507-19.
31. Zajicek J., Ball S., Wright D. et al.: Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013; 12(9): 857-65.
2. Rizzo M.A., Hadjimichael O.C., Preingerova J. et al.: Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 2004; 10(5): 589-595.
3. Grotenhermen F., Müller-Vahl K.: The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl. Int. 2012; 109(29-30): 495-501.
4. Leussink V.I., Husseini L., Warnke C. et al.: Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Ther. Adv. Neurol. Disord. 2012; 5(5): 255-66.
5. Fankhauser M.: Cannabis in der westlichen Medizin Cannabis und Cannabinoide. W: Pharmakologie, Toxikologie und therapeutisches Potential. Grotenhermen F. (red.). Wyd. 2. Hans Huber, Göttingen, 2004: 57-71.
6. Consroe P., Musty R., Rein J. et al.: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 1997; 38(1): 44-8.
7. Clark A.J., Ware M.A., Yazer E. et al.: Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004; 62(11): 2098-100.
8. Zajicek J., Fox P., Sanders H. et al.; UK MS Research Group: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517-26.
9. Zajicek J.P., Sanders H.P., Wright D.E. et al.: Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J. Neurol. Neurosurg. Psychiatry 2005; 76(12): 1664-9.
10. Wade D.T., Makela P., Robson P. et al.: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 2004; 10(4): 434-41.
11. Collin C., Davies P., Mutiboko I.K. et al., Sativex Spasticity in MS Study Group: Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 2007; 14(3): 290-6.
12. Novotna A., Mares J., Ratcliffe S. et al., Sativex Spasticity Study Group: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 2011; 18(9): 1122-31.
13. Freidel et al.: Treatment of specific symptoms session. Fri. 4, Oct. 15:30–17:30. P1111. ECTRIMS 2013.
14. Wright et al.: Late Breaking News session. Fri. 4, Oct. 15:30–17:30. P1206. ECTRIMS 2013.
15. Eltayb et al.: Long-term treatment monitoring session. Fri. 4, Oct. 15:30–17:30. P1041. ECTRIMS 2013.
16. García-Merino A.: Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev. Neurother. 2013; 13(3 Suppl 1): 9-13.
17. Hilliard A., Stott C., Wright S. et al.: Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis. ISRN Neurol. 2012; 2012: 802649.
18. Arroyo R., Massana M., Vila C.: Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int. J. Neurosci. 2013; 123(12): 850-8.
19. Rizzo M.A., Hadjimichael O.C., Preingerova J. et al.: Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 2004; 10(5): 589-595.
20. Montalban X., Wright S.: Trial period for new symptomatic treatments: lessons learnt from a Sativex in MS spasticity clinical trial. Mult. Scler. 2009; 15: S272.
21. Svendsen K.B., Jensen T.S., Bach F.W.: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460): 253.
22. Rog D.J., Nurmikko T.J., Friede T.: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812-9.
23. Langford R.M., Mares J., Novotna A. et al.: A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J. Neurol. 2013; 260(4): 984-97.
24. Kavia R.B., De Ridder D., Constantinescu C.S. et al.: Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler. 2010; 16(11): 1349-59.
25. Zajicek J.P., Apostu V.I.: Role of cannabinoids in multiple sclerosis. CNS Drugs 2011; 25(3): 187-201.
26. Corey-Bloom J., Wolfson T., Gamst A. et al.: Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 2012; 184(10): 1143-50.
27. Aldington S., Harwood M., Cox B. et al.: Respiratory Disease Research Group. Cannabis use and risk of lung cancer: a case-control study. Eur. Respir. J. 2008; 31(2): 280-6.
28. de Lago E., Moreno-Martet M., Cabranes A. et al.: Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 2012; 62(7): 2299-308.
29. Hasseldam H., Johansen F.F.: Cannabinoid treatment renders neurons less vulnerable than oligodendrocytes in Experimental Autoimmune Encephalomyelitis. Int. J. Neurosci. 2011; 121(9): 510-20.
30. Kozela E., Lev N., Kaushansky N. et al.: Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosislike disease in C57BL/6 mice. Br. J. Pharmacol. 2011; 163(7): 1507-19.
31. Zajicek J., Ball S., Wright D. et al.: Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013; 12(9): 857-65.